We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 2,112

China tightens controls over commercial bribery in the health care industry -
  • Ropes & Gray LLP
  • China, USA
  • January 3 2014

As of March 1, 2014, the China National Health and Family Planning Commission (the "Commission") will compile bribery blacklists in the health care

China reorganizes the SFDA and appoints a new commissioner
  • Covington & Burling LLP
  • China
  • March 25 2013

China's 12th National People's Congress has recently approved a plan to consolidate most of the country's regulatory authority over food into a

China releases vaccine good clinical practices
  • Ropes & Gray LLP
  • China
  • November 9 2013

On October 31, 2013, The China Food and Drug Administration ("CFDA") promulgated a regulation titled Guiding Principles for the Quality Management of

China solicits comments on good supply practices for medical devices
  • Ropes & Gray LLP
  • China, USA
  • January 10 2014

The China Food and Drug Administration (the "CFDA") recently published a draft regulation, Good Supply Practices for Medical Devices (the "Draft

Chinese FDA released guidelines for Rx-OTC switch
  • Ropes & Gray LLP
  • China
  • December 5 2012

The State Food and Drug Administration (“SFDA”) recently announced a set of technical guidelines for switching prescription drugs to over-the-counter drugs (“Rx-OTC Switch Guidelines”

China SFDA creates new regulatory pathways for transfer of drug licenses
  • Ropes & Gray LLP
  • China
  • March 4 2013

To accelerate GMP compliance by domestic pharmaceutical companies, the Chinese State Food and Drug Administration ("SFDA") published a notice on

Global Pricing Newsletter: volume two
  • Sidley Austin LLP
  • China, Global, United Kingdom, USA
  • February 27 2013

Pharmaceutical and biologic manufacturers operate in an increasingly global economy where legal developments in one market may have cascading impacts

China's life sciences regulatory crackdown
  • Reed Smith LLP
  • China
  • September 10 2013

The regulatory enforcement environment in China remains tense, as both the Chinese government and media bring new actions and allegations against

The promotion of private healthcare services- a challenge or an opportunity?
  • King & Wood Mallesons
  • China
  • April 18 2013

To address China's aging population issue as well as its need to improve access to healthcare in rural areas, healthcare reform has become a priority

Gilead’s Viread patent found invalid in China
  • Marks & Clerk
  • China
  • December 17 2013

Earlier this year, the Patent Review Board of China's State Intellectual Property Office (SIPO) rejected Gilead Sciences' claims regarding their